Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, with Intravenous GTX-104 Meeting All Endpoints

Acasti Pharma Inc. announced that the top line results of its pharmacokinetic bridging study with IV GTX-104, the Company’s lead drug candidate for the treatment of Subarachnoid Hemorrhage , met all its planned study endpoints.
[Acasti Pharma Inc.]
Press Release

Stay up-to-date with your field!

Subscribe for free weekly science newsletters.

Related News